相关临床试验
136
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1979
进行中（未招募）
3
2.2%
已完成
50
36.8%
尚未招募
8
5.9%
招募中
23
16.9%
终止
5
3.7%
Unknown
45
33.1%
撤回
2
1.5%
暂无批准数据
- Hamad Medical Corporation laboratories perform over 20 million diagnostic tests annually, including approximately 153,000 genetic tests for inherited disorders, blood cancers, and newborn screening. - HMC has launched in-house Clinical Whole Exome Sequencing for the first time, alongside new pharmacogenomics and thrombophilia testing services to advance personalized medicine. - The Cell Therapy Laboratory reported a 19% increase in stem cell-based bone marrow transplants for adult cancer patients compared to the previous year. - Qatar has achieved blood transfusion self-sufficiency and introduced cryopreservation technology enabling rare blood group red cell storage for up to 30 years.
- Hamad Medical Corporation has signed a memorandum of understanding with AbbVie Biopharmaceuticals Gulf Levant to implement the Clinical Research Advancement Integrated Signature Programme (CRISP) at HMC. - The program provides clinical research professionals with world-class training, internationally recognized certification through ACRP, and ongoing professional support in areas including good clinical practice and patient safety. - CRISP has demonstrated regional success with over 700 certificates awarded to participants from more than 15 countries and has received accreditation from major health authorities. - The partnership aims to strengthen Qatar's clinical research capacity, improve patient outcomes, and position the country as a leader in medical innovation.
